Upregulation of TREM2 Ameliorates Neuropathology and Rescues Spatial Cognitive Impairment in a Transgenic Mouse Model of Alzheimer’s Disease

Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K et al (2012). An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J Neurosci 32: 9677–9689.

Burgess N, Maguire EA, O'Keefe J (2002). The human hippocampus and spatial and episodic memory. Neuron 35: 625–641.

Calkins MJ, Reddy PH (2011). Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons. Biochim Biophys Acta 1812: 507–513.

Colonna M (2003). TREMs in the immune system and beyond. Nate Rev Immunol 3: 445–453.

Daws MR, Lanier LL, Seaman WE, Ryan JC (2001). Cloning and characterization of a novel mouse myeloid DAP12-associated receptor family. Eur J Immunol 31: 783–791.

Dodart JC, Marr RA, Koistinaho M, Gregersen BM, Malkani S, Verma IM et al (2005). Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 102: 1211–1216.

Frank S, Burbach GJ, Bonin M, Walter M, Streit W, Bechmann I et al (2008). TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia 56: 1438–1447.

Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E (2010). Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer’s disease. Acta Neuropathol 119: 523–541.

Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K et al (2013). Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78: 631–643.

Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E et al (2013). TREM2 variants in Alzheimer's disease. N Engl J Med 368: 117–127.

Hamerman JA, Jarjoura JR, Humphrey MB, Nakamura MC, Seaman WE, Lanier LL (2006). Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunol 177: 2051–2055.

Hensley K (2010). Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. J Alzheimer's Dis 21: 1–14.

Hsieh CL, Koike M, Spusta SC, Niemi EC, Yenari M, Nakamura MC et al (2009). A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem 109: 1144–1156.

Ito H, Hamerman JA (2012). TREM-2, triggering receptor expressed on myeloid cell-2, negatively regulates TLR responses in dendritic cells. Eur J Immunol 42: 176–185.

Jiang T, Yu JT, Zhu XC, Tan L (2013). TREM2 in Alzheimer's disease. Mol Neurobiol 48: 180–185.

Jiang T, Yu JT, Zhu XC, Tan MS, Gu LZ, Zhang YD et al (2014a). Triggering receptor expressed on myeloid cells 2 knockdown exacerbates aging-related neuroinflammation and cognitive deficiency in senescence-accelerated mouse prone 8 mice. Neurobiol Aging 35: 1243–1251.

Jiang T, Yu JT, Zhu XC, Tan MS, Wang HF, Cao L et al (2014b). Temsirolimus promotes autophagic clearance of amyloid-beta and provides protective effects in cellular and animal models of Alzheimer's disease. Pharmacol Res 81: 54–63.

Jin JJ, Kim HD, Maxwell JA, Li L, Fukuchi K (2008). Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J Neuroinflamm 5: 23.

Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J et al (2013). Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368: 107–116.

Kapadia M, Sakic B (2011). Autoimmune and inflammatory mechanisms of CNS damage. Progr Neurobiol 95: 301–333.

Kiialainen A, Hovanes K, Paloneva J, Kopra O, Peltonen L (2005). Dap12 and Trem2, molecules involved in innate immunity and neurodegeneration, are co-expressed in the CNS. Neurobiol Dis 18: 314–322.

Larson ME, Lesne SE (2012). Soluble Abeta oligomer production and toxicity. J Neurochem 120 (Suppl 1): 125–139.

Liu S, Liu Y, Hao W, Wolf L, Kiliaan AJ, Penke B et al (2012). TLR2 is a primary receptor for Alzheimer's amyloid beta peptide to trigger neuroinflammatory activation. J Immunol 188: 1098–1107.

Meda L, Baron P, Scarlato G (2001). Glial activation in Alzheimer's disease: the role of Abeta and its associated proteins. Neurobiol Aging 22: 885–893.

Melchior B, Garcia AE, Hsiung BK, Lo KM, Doose JM, Thrash JC et al (2010). Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease. ASN Neuro 2: e00037.

Moreno-Gonzalez I, Estrada LD, Sanchez-Mejias E, Soto C (2013). Smoking exacerbates amyloid pathology in a mouse model of Alzheimer's disease. Nat Commun 4: 1495.

Neumann H, Daly MJ (2013). Variant TREM2 as risk factor for Alzheimer's disease. N Engl J Med 368: 182–184.

Neumann H, Takahashi K (2007). Essential role of the microglial triggering receptor expressed on myeloid cells-2 (TREM2) for central nervous tissue immune homeostasis. J Neuroimmunol 184: 92–99.

Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R et al (2002). Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet 71: 656–662.

Paradowska-Gorycka A, Jurkowska M (2013). Structure, expression pattern and biological activity of molecular complex TREM-2/DAP12. Hum Immunol 74: 730–737.

Piccio L, Buonsanti C, Mariani M, Cella M, Gilfillan S, Cross AH et al (2007). Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis. Eur JImmunol 37: 1290–1301.

Takahashi K, Prinz M, Stagi M, Chechneva O, Neumann H (2007). TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS Med 4: e124.

Takahashi K, Rochford CD, Neumann H (2005). Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 201: 647–657.

Tan MS, Yu JT, Jiang T, Zhu XC, Guan HS, Tan L (2014). IL12/23 p40 inhibition ameliorates Alzheimer's disease-associated neuropathology and spatial memory in SAMP8 mice. J Alzheimer's Dis 38: 633–646.

Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L et al (2006). Cutting edge: TREM-2 attenuates macrophage activation. J Immunol 177: 3520–3524.

Varvel NH, Bhaskar K, Kounnas MZ, Wagner SL, Yang Y, Lamb BT et al (2009). NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J Clin Invest 119: 3692–3702.

Walsh DM, Selkoe DJ (2004). Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44: 181–193.

Wyss-Coray T (2006). Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 12: 1005–1015.

Yan Y, Wang C (2006). Abeta42 is more rigid than Abeta40 at the C terminus: implications for Abeta aggregation and toxicity. J Mol Biol 364: 853–862.